文章：

双特异性抗体与T细胞导向疗法在非霍奇金淋巴瘤中的现状

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL

原文发布日期：31 March 2025

DOI: 10.3390/cancers17071192

类型: Article

开放获取: 是

英文摘要：

Relapsed/refractory non-Hodgkin lymphoma (r/r/NHL) is an aggressive disease with overall poor response rates to chemo-immunotherapy and autologous stem-cell transplant, especially in patients with diffuse large B-cell lymphoma. Major improvements in this disease space have come through the incorporation of novel immune therapies, including CD19/CD20 directed CAR-T cells and bispecific antibodies. These exciting new therapies continue to change the landscape of treatment for r/r NHL and have been incorporated in earlier lines of therapy with demonstrated efficacy and patient safety. In this review, the role of these treatments in the management of relapsed/refractory NHL is discussed in detail along with future directions of research.

摘要翻译： 

复发/难治性非霍奇金淋巴瘤（r/r NHL）是一种侵袭性疾病，对化学免疫疗法和自体干细胞移植的总体反应率较低，尤其是在弥漫性大B细胞淋巴瘤患者中。该疾病领域的重大进展主要得益于新型免疫疗法的引入，包括靶向CD19/CD20的CAR-T细胞和双特异性抗体。这些令人振奋的新疗法持续改变着r/r NHL的治疗格局，并已应用于更早期的治疗阶段，其疗效和患者安全性已得到验证。本综述将详细探讨这些疗法在复发/难治性非霍奇金淋巴瘤治疗中的作用，并展望未来的研究方向。

原文链接：

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL